Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743934 · ClinicalTrials.gov registry record · Phase 2
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
A Phase 2 study of Prostate Adenocarcinoma, sponsored by Andrew McDonald.
- Active
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT04743934 is a Phase 2 study of Prostate Adenocarcinoma that is active but no longer recruiting, run by Andrew McDonald. The registered enrollment target is 44 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04743934, a Phase 2 study of Prostate Adenocarcinoma, is active but no longer recruiting, sponsored by Andrew McDonald.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Androgen deprivation therapy
- DRUG Flibanserin 100 MG
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04743934
The ClinicalTrials.gov registry entry for NCT04743934 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (80% lower). The listed sponsor is Andrew McDonald, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04743934 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT04743934 about?
NCT04743934 is a clinical study titled "Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer". This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.
What is the current status of trial NCT04743934?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2021-07-02. Estimated completion is 2026-03.
What conditions does trial NCT04743934 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT04743934?
The interventions under investigation include: Placebo (DRUG), Androgen deprivation therapy (DRUG), Flibanserin 100 MG (DRUG).
Who is sponsoring clinical trial NCT04743934?
This trial is sponsored by Andrew McDonald, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04743934 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.